A carregar...
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
We report pharmacokinetics, efficacy and safety data for a new 150‐mg alectinib capsule in ALK+ non‐small‐cell lung cancer in a multicenter, open‐label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor‐naïve and ‐pretreated [includin...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5132270/ https://ncbi.nlm.nih.gov/pubmed/27566263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13066 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|